Burzynski: ANAPLASTIC ASTROCYTOMA (AA)

� � � � � � � � � � � � � � � � �
# and % of Patients Resolving or Stabilizing Disease = Complete Response + Partial Response + Stable Disease
——————————————————————
14 / 70% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)

13 / 65% – 10/2008 – Protocol – Antineoplastons: PATIENTS WITH Newly Diagnosed ANAPLASTIC ASTROCYTOMA (AA)

11 / 61% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
======================================
# and % of Patients Showing Objective Response = Complete Response + Partial Response
——————————————————————
5 / 25% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)

5 / 25% – 10/2008 – Protocol – Antineoplastons: PATIENTS WITH Newly Diagnosed ANAPLASTIC ASTROCYTOMA (AA)

4 / 22% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
======================================
# and % of Patients Showing Complete Response
——————————————————————
5 / 25% – 10/2008 – Protocol – Antineoplastons: PATIENTS WITH Newly Diagnosed ANAPLASTIC ASTROCYTOMA (AA)

16% – Antineoplastons: RECURRENT Anaplastic Astrocytoma (AA)

3 / 15% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)

2 / 11% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
======================================
# and % of Patients Showing Partial Response
——————————————————————
2 / 11% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)

2 / 10% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)
======================================
# and % of Patients Showing Stable Disease
——————————————————————
9 / 45% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)

8 / 40% – 10/2008 – Protocol – Antineoplastons: PATIENTS WITH Newly Diagnosed ANAPLASTIC ASTROCYTOMA (AA)

7 / 39% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
======================================
# and % of Patients Showing Progressive Disease
——————————————————————
7 / 39% – 3/2006 – (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – Antineoplastons: recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)

7 / 35% – 10/2008 – Protocol – Antineoplastons: PATIENTS WITH Newly Diagnosed ANAPLASTIC ASTROCYTOMA (AA)

6 / 30% – 12/2008 – Protocol – Antineoplastons: ADULT PATIENTS WITH recurrent ANAPLASTIC ASTROCYTOMA (AA)
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
======================================
Maximum Survival for Patient with recurrent, diffuse, intrinsic anaplastic ASTROCYTOMA:
——————————————————————
17+ years (approaching 18 years) – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
======================================
Follow-up for some:
——————————————————————
17 years – Antineoplastons (ANP) Targeted Therapy: ASTROCYTOMAS (Pgs. 174 + 177) Treatments for Astrocytic Tumors 2006
======================================
Patient with GLIOBLASTOMA:
——————————————————————
(6+ years – Patient with recurrent, diffuse, intrinsic GLIOBLASTOMA MULTIFORME (GBM))
======================================
Survival in recurrent diffuse intrinsic GLIOBLASTOMAS and anaplastic ASTROCYTOMAS of the BRAINSTEM in a small group of Patients:
——————————————————————
5+ years – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
======================================
Patient with GLIOBLASTOMA:
——————————————————————
5+ years – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
======================================
substantial # Tumor Free:
——————————————————————
5+ years – Antineoplastons (ANP) Targeted Therapy: ASTROCYTOMAS (Pgs. 174 + 177) Treatments for Astrocytic Tumors 2006
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
44% – ANAPLASTIC ASTROCYTOMA (AA): 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
35% – radical resection: 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
29 / 22% – ANAPLASTIC ASTROCYTOMA (AA): less aggressive surgery – 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
17% – less aggressive procedure: 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
5 year Overall Survival:
——————————————————————
22% – 3/2006 Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
======================================
Most Patients with Newly Diagnosed High-Grade BRAIN STEM GLIOMAS (HBSG) don’t Survive more than:
——————————————————————
2+ years – (Pgs. 40 +45-46)
======================================
2 year Overall Survival:
——————————————————————
39% – 3/2006 Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
======================================
Most Patients with BRAINSTEM GLIOMA fail standard radiation therapy and chemotherapy and don’t survive longer:
——————————————————————
2 years – (Pgs. 40 + 45-46)
======================================
Patients with Recurrent Tumors Survive no more than, despite standard treatment:
——————————————————————
6 months – (Pgs. 40 + 45-46)
======================================
Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS:
Progression-Free Survival (PFS) at 6 months:

——————————————————————
39% – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
======================================
Median Progression-Free Survival (PFS):
——————————————————————
5.28 months – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pg. 45)
======================================
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
� � � � � � � � � � � � � � � � �
Burzynski: Progression-Free Survival:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
� � � � � � � � � � � � � � � � �

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s